Community Voices for 340B is a nonprofit dedicated to educating the public about the importance of the 340B program and leading the collective action needed to bring a voice to the real beneficiaries of the 340B program.
We are a grassroots organization that enables community members to tell their side of the story: why 340B is vital to them, and why a sustained and vibrant 340B program is an essential tool to ensuring healthcare access among the most needy.
A Gift of Any Size Will Make an Impact!
Every dollar helps CV340B amplify the voices of patients, communities, and healthcare providers who rely on the 340B program. Our almost entirely volunteer-led organization relies on the generosity of the 340B community to produce far-reaching and impact advocacy and organizing efforts. With your support, we will have the strength and resources fo #defend340B from major drug companies seeking to destroy this vital program.
For more information, please contact Rhiannon Marshall at Rhiannon.Marshall@CV340B.org
Contributions to CV340B, a D.C. nonprofit corporation Internal Revenue Code section 501(c)(3) charitable organization, are tax deductible.
To make a donation via check, make payable to CV340B and mail it to:
Attn: Traci Leith
CV340B
161 Gaither Drive, Suite 201
Mount Laurel, NJ 08054
Other Ways to Support!
Campaign Sponsorships
As a Campaign Sponsor, CV340B will work with you to create a customized digital engagement employing one or more of the following options.
Get Involved
There are many ways to get involved to #Defend340B, click below to get started on your 340B Advocacy Journey!
Subscribe to ActionAlerts
Get all the latest from CV340B and stay connected with the #Defend340B community!
"*" indicates required fields
340B is a lifeline to the neediest and most underserved patients.
First established in 1992 through bipartisan legislation, the federal 340B drug discount program offers a lifeline to the neediest and most underserved patients in this nation. The program operates on the simple principle of requiring pharmaceutical companies to provide drugs at a discounted price to certain types of safety net hospitals and clinics that, in turn, use their 340B savings to underwrite the cost of serving patients in their communities.